Both neutralizing antibodies and cytotoxic T-cells are necessary to control a viral infection.
Persistent viral infections are characterized by a deficient CD4 + T cell function, whereas the presence of a strong Th response defines successful viral clearance. These findings have important implication in designing vaccination strategies aimed to trigger and sustain antigen specific CD4 + in addition to CD8 + effector immune responses [1, 2] .
CD4
+ T cell responses are more and more important in immunity to HIV-1 [3] . Infected humans that control HIV-1 replication and remain disease free for years after infection display a potent Th response [4] . In HIV-1 vaccine preclinical studies, although CD8 + T cell
and neutralizing antibody responses have demonstrated to be critical in protecting animals from infection and/or disease, they are not sufficient to provide solid protective anti-HIV-1 immunity [5] unless the appearance of a strong virus-specific CD4 + T cell response, characterized by proliferating elements [3, 6, 7] . Thus, the induction of CD4 + T cell responses is a fundamental characteristic of an ultimate anti-HIV-1 vaccine candidate.
Professional APCs play a key role in the development of primary T cell immune response [8] . Dendritic cells (DCs) and macrophages, are permissive to HSV-1 infection [9] [10] [11] . Using a recombinant HSV-1 capable of a single replicative cycle, Salio et al. [12] showed that synthesis of MHC class II antigens is up-regulated or unaffected in infected immature and mature DCs, respectively.
In this study, we show that a recombinant replication-deficient (rd) HSV vector encoding the cytosolic HIV-1 matrix protein p17 (T0-p17), a protein that is suggested to play a role in 4 AIDS pathogenesis [13] and reported as a possible candidate for an AIDS vaccine, is capable to efficiently infect professional APCs in vitro and in vivo. Immunization of mice with T0-p17 generates a T helper response able to trigger both p17-specific humoral and effector responses.
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Materials and Methods
Generation of the p17-expressing rdHSV
A p17-expressing rdHSV vector was produced as previously described [14] . A recombination HSV-plasmid containing the HIV-p17 was constructed by cloning the Rev-independent coding sequence of p17 (kindly provided by G. Pavlakis, Frederick, MD; GenBank Accession number L04602). The genome of a non-replication HSV-1 viral vector expressing the Green Fluorescent Protein (GFP) (T0-GFP) was used to recombine with the p17 plasmid (T0-p17). The T0-p17 vector provides a robust, but very transient, GFP expression while it ensures a long-lasting transgene expression [15] . In all the experiments the vector T0-GFP was used as negative control. Protein expression from the T0-p17 vector was analyzed using anti-p17 mAb MBS-3 as specific reagent [13] .
Cell cultures
Splenocytes, peritoneal macrophages and bone marrow-derived DCs (BMDCs) from BALB/c mice were cultured in RPMI-1640 (Sigma) medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin (complete medium).
Vaccination of mice
BALB/c mice were purchased from Charles River International (Calco, Lecco, Italy).
Animals were maintained in vented cages under standard conditions according to our institutional guidelines. Animals were divided in four groups of fifteen mice each, and the 6 mice were each immunized with 4 x 10 6 virus particles of T0-p17 or T0-GFP by intradermal (i.d.) or intraperitoneal (i.p.) injection. Five mice in each group were sacrificed at day 6, at day 11 and day 35 after immunization.
Generation of DCs from bone marrow precursors.
BMDCs were prepared from female six-to nine-week-old mice using a modification of the protocol from Inaba et al. [16] . Briefly, after lysis of erythrocytes, 1x10 8 bone marrow cells were plated on 100-mm Petri dishes and, after 2 hours, non-adherent cells were transferred in 6-well-plates at 2x10 6 cells/ml in complete medium supplemented with GM-CSF (10 ng/ml; R&D Systems, Minneapolis, MN). On day 6, cells were 84-88% CD11c + .
Proliferation assays
For proliferation experiments splenocytes were seeded in 96-well U-bottom culture plates at a density of 2x10 5 cells/well in complete medium and grown in the presence or absence (as negative control) of recombinant p17 [13] (10 μg/ml) for 6 days. At day 5 cells were pulsed with 1 μCi of [ 3 H]-thymidine (Amersham Biosciences) and harvested after 18 hours. fluorescence were included for analysis.
Flow cytometry
Immunohistochemistry
Mice were infected intradermally with 4x10 6 T0-p17 virus particles/mouse. Tissue specimens were taken 12, 24 or 36 hours p.i. through punch biopsy, mounted in Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA) and frozen in liquid nitrogen precooled isopenthane. Five-micron sections were air-dried overnight and fixed in acetone for 10 min.
Sections were incubated with 10% normal goat serum for 20 minutes, followed by hamster anti-mouse CD11c (BD Biosciences) and rabbit anti-GFP (Santa Cruz Biotechnology); primary antibodies were then revealed with biotin-conjugated goat anti-hamster IgG (Vector, Burlingame, CA) followed by Texas red-conjugated streptavidin (Vector), and with FITC conjugated swine anti-rabbit antibody (Dako, Carpinteria, CA), respectively. Sections were photographed on the Olympus BX60 fluorescence microscope using the DP70 Olympus digital camera.
Measurement of cytokines and chemokines
Culture supernatants were assayed for the presence of interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6 and monocyte chemoattractant protein (MCP)-1 by flow cytometry, using the Cytometric Bead Array (BD Biosciences).
Enzime-linked Immunospot (ELISPOT) assay
For the evaluation of p17-specific IFN-γ-producing CD8, CD4 were removed from splenocytes using a magnetic bead system (Miltenyi Biotec, Bologna, Italy 
ELISA for anti-p17 antibody detection
For detection of anti-p17 specific antibodies, sera were pooled and tested by a recombinant p17-based ELISA [17] . Serum pools were obtained by mixing 10 μl of serum taken from each mouse belonging to the same experimental group.
Isolation and infection of peritoneal macrophages
Mice were sacrificed and macrophages were obtained by flushing the peritoneal cavity of the animals with sterile PBS. Peritoneal macrophages were purified by adhesion to plastic for 2 hours. Adherent cells were scraped, resuspended (5x10 5 /200 μl) in RPMI 1640 in the absence of FBS and infected with T0-GFP and T0-p17 at 1 m.o.i.
Extraction and amplification of nucleic acids
DNA extraction was performed by QIAmp DNA blood mini kit (Qiagen) and detection of p17 amplicons was performed using PCR (forward 5'-AGGGAGCTAGAACGATTCGCAG-3'; reverse 5'-TGATTGCTGTGTCCTGTGTCAG-3'); or a nested-PCR approach when 9 necessary (forward 5'-CTGTAGACAAATACTGGGACAGC-3'; reverse 5'-TGTCTA AAGCTTCCTTGGTGT C-3'). To evaluate the presence of p17 transcripts, RNA was extracted by RNAeasy minikit (Qiagen) and DNA contamination in RNA preparations was eliminated by digestion with 1500 U of RNase-free DNase (Quiagen). RNA (1 μg) was then reverse-transcribed using MULV reverse transcriptase (Applera, Monza, Italy) and used as a template for PCR. To demonstrate the absence of DNA contamination, an aliquot of RNA sample was amplified without previous retrotranscription.
Results
Expression of p17 in cells infected with T0-p17
Expression of p17 in T0-p17 infected simian (Vero), human (293) and mouse (G16-9) cells was examined by Western blot. The cells were infected with either T0-p17 or T0-GFP vectors at a m.o.i. of 1. In all three types of cells infected with T0-p17 vector we observed, at 24 and 48 hours, a band of 17 kDa corresponding to p17, whereas in cells infected with T0-GFP control vector, there were no signs of detectable bands ( Fig. 1 ).
Recombinant T0-p17 vector efficiently infects DCs in vitro and in vivo
HSV has been shown to efficiently infect DCs [18] . Little is known, however, about the trasduction efficiency of replication-deficient HSV-1 vectors both in vitro and in vivo. The capability of T0-p17 to transduce intradermal DCs in vivo was confirmed by i.d.
injection with 4x10 6 virus particles of T0-p17. As shown in Fig. 2b , sparse CD11c + cells
were identified in the dermis of uninfected mice whereas no labelling was found on anti-GFP stained sections. In contrast, as soon as 12 hours after T0-p17 injection, biopsies showed several GFP + spindle cells in the dermis that, in the majority of the cases, co-expressed CD11c.
T cell proliferation of splenocytes from T0-p17 vaccinated mice in response to p17 as a recall antigen
To assess the immunogenicity of endogenously produced p17, mice were immunized by i.d.
or i.p. injection of T0-p17. As negative vaccination control we employed the T0-GFP vector.
Splenocytes obtained from T0-vaccinated mice were stimulated in vitro with p17 and proliferative activity was measured after 6 days of incubation. A p17-specific T cell proliferative response was observed in T0-p17 immunized mice but not in mice immunized with the T0-GFP control vector. As shown in Fig. 3a , p17 specific T cell clones were absent at day 6 after T0-p17 immunization but were generated at day 11 after virus injection. A more pronounced proliferative activity was observed in cells obtained from i.d. injected mice as compared to cells obtained from i.p. injected animals. Flow cytometric analysis showed that most of the expanded cells in response to p17 were CD4 + T-cells (Fig. 3b) .
T0-p17 generates p17 specific CD8 + and humoral immune responses
At day 6 and 11 after immunization of mice with T0-p17 there was no evidence for the generation of a p17-specific effector response, as IFN-γ was not detected in the supernatant of p17 stimulated cultures (Fig. 4a ) and a very low number of IFN-γ-producing CD8 + T-cells was evidenced by ELISPOT assay (Fig. 4b) . Moreover, antibodies to p17 were not detected in sera of immunized mice (Fig. 4c ). Mice immunized with T0-p17 and sacrificed at day 35
showed a p17-dependent T cell proliferation that was superimposable to that observed in 12 splenocyte cultures of mice sacrificed at day 11 after virus injection (Fig. 3a) . However, 35 days after T0-p17 injection, all mice developed also a p17-specific effector response.
Splenocytes obtained from these animals contained a great number of p17 specific IFN-γ producing cells as assessed by a peptide-based ELISPOT and ELISA assays, compared to splenocytes obtained from mice immunized with the T0-GFP control vector (Fig. 4b) .
Concomitantly, a p17 specific humoral response was detected in T0-p17-immunized animals (Fig. 4c) . It is worth noting that i.d. delivery of T0-p17 elicited a better effector response than the i.p. delivery route.
T0-p17 vector efficiently infects peritoneal macrophages
Experiments were performed to test the capability of T0-p17 to infect freshly collected murine peritoneal macrophages in vitro. As shown in Fig. 5a , peritoneal macrophages showed a good susceptibility to T0-p17 infection (m.o.i. of 1), as more than 30% were infected 48 hours after infection. The capability of T0-p17 to infect peritoneal macrophages was also assessed in vivo, by injecting mice i.p. with 4x10 6 T0-p17 virus particles/mouse.
Infection of macrophages with T0-p17 was assessed by nested PCR. The p17 transgene was detected in peritoneal macrophages at 2 and 11 days after T0-p17 injection (Fig. 5b) .
Moreover, following i.p. injection of the T0-p17 vector, the transgene carried by rdHSV was detectable at day 6, 11 and 35 days after viral infection in the spleen of animals, where it persisted up to eight months (Fig. 5c ). (Fig. 6b) . Analysis of cytokines and chemokines in the supernatant of long-term self-maintaining mixed cultures revealed the presence of high amounts of proinflammatory molecules, attesting the strong activation status of cells in the microenvironment. In particular, TNF-α (range from 0.6 to 0.9 ng/ml), IL-6 (range from 1.3 to 2.2 ng/ml) and MCP-1 (range from 0.8 to 1.6 ng/ml) were constantly detected. On the contrary, a selflimiting proliferation of p17 specific T-cells, lasting no more than 7 days, was obtained by 14 mixing peritoneal macrophages obtained from uninfected mice with splenocytes of T0-p17 immunized mice (1:20 ratio) and using exogenous recombinant p17 as a recall antigen (data not shown). Interestingly, T0-p17 genome and p17 transcripts were detected in adherent
T0-p17 infected APCs promote the long-term expansion of p17 specific CD4 + T cell clones in vitro
APCs at the end of coculture (30 days) by PCR and RT-PCR, respectively (Fig. 6c) . These results confirm the long-lasting persistence of the viral vector in the in vivo transduced APCs and its capability to allow the long-term expression of the transgene. On the other hand, adherent APCs did not show any p17 protein expression during the coculture period either by immunofluorescence assay, or by western blot (Data not shown), using anti-p17 mAb MBS-3 as specific reagent [13] . The observation that p17 transripts persisted for all the period of culture, as revealed by RT-PCR, might be due to the greater sensitivity of this assay. Taken together, these results show that professional APCs are suitable targets for HSV-derived viral vectors and that they provide an optimal presentation of endogenously produced HIV-1 p17
in MHC class II molecules.
Discussion
rdHSV vectors have been largely restricted to suicide- [19] or cytokine gene [20] therapy against tumors but recently published studies have shown the potential of these viral vectors also for vaccination [21, 22] . tropism that includes APCs [9] . In this study we show that DCs can be efficiently transduced by rdHSV vectors both in vitro and in vivo. In our experiments we found that BMDCs were The priming of antigen specific CD4 + T-cells requires the presentation of antigenic peptides in the context of MHC class II molecules. This is usually achieved by the uptake of extracellular antigens [24] . On the other hand, there are accumulating evidences that endogenously expressed proteins have also access to the MHC class II-restricted antigen presentation pathway [25] [26] . Our data suggest a correct MHC class II processing of endogenously produced p17 by professional APCs. The capability of T0-p17 to transduce professional APCs without disturbing the processes leading to a correct endogenous antigen processing and presentation in the MHC class II molecules was confirmed by experiments performed on peritoneal macrophages. These cells were found to be susceptible to T0-p17 both in vitro and in vivo. In particular, in vivo infected peritoneal macrophages were capable to sustain the expansion of p17 specific CD4 + T-cells obtained from mice vaccinated i.d. with T0-p17.
It is interesting to note that, differently from processing of exogenous p17, persistence of the p17 transcripts in peritoneal macrophages as well as the correct presentation of p17 peptides within MHC class II molecules led to the development of self-maintaining macrophage/T cell mixed cultures. The limited expansion of specific Th clones following exogenous antigen stimulation is explained by the physiological removal of MHC class II/peptide complexes following T cell dissociation from the immunological synapse that limits their availability to other T-cells over time [27] . On the other hand, the generation of self-maintaining cocultures following presentation of antigens by rdHSV transduced macrophages finds a possible explanation in the continuous production of endogenous antigens and re-expression of newly synthesized p17 peptides on nascent or recycling MHC class II molecules [28] . This may ultimately lead to the maintenance of full Th cell activation and consequently, to a suitable microenvironment for macrophage survival [29] .
Co-cultivation of T0-p17 infected macrophages with splenocytes of T0-GFP immunized mice did not give rise to any T cell expansion in vitro. This finding may be explained by the knowledge that a strong and detectable Th response mostly depends on the nature of the antigen [30] . Our hypothesis is supported by the recent finding that mice immunized with the same rdHSV vector we used to perform experiments, but expressing the HIV-1 tat transgene, did not trigger the development of any detectable tat-specific Th response, despite the generation of an effective CTL response [14] . However, we can not completely rule out that rdHSV-or GFP-specific CD4 + Th responses can be elicited in T0-p17 vaccinated mice, and that they are not detectable under our experimental conditions. In fact, it is not known whether peritoneal macrophages may allow the adequate processing and MHC class II presentation of rdHSV-or GFP-derived peptides leading to the proliferation of specific Th clones. Whatever the reason may be, our data provide evidence that T0-p17 vector is a powerful tool to detect and expand CD4 + p17-specific cells. It is worth noting that following i.p. injection of T0-p17 vector, the transgene carried by rdHSV was detectable up to eight months in the spleen of animals. Taken together, these results demonstrate, for the first time, that rdHSV vectors persist in the host suggesting a durable transgene expression which may enhance the magnitude and longevity of immune responses.
In conclusion, our data provide evidence that T0-p17 vector may closely mimic the in vivo processing events, as the p17 trangene is synthesized and presented within the APCs.
Because of their capability to infect professional APCs, their long-lasting persistence in such non dividing cells and lack of interference with APCs' functions, rdHSV vectors have to be considered strong candidates as antigen delivery system for vaccine development. This is particularly important in the context of AIDS vaccines, which require the generation of strong specific CD4 + T-cell responses for providing solid protective immunity. 
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